Treats active duodenal ulcer. Sold as Prevacid, Prevacid Iv, Prevacid 24 Hr, Lansoprazole. Every FDA application for this active ingredient: 6 branded and 30 generic.
As of Nov 16, 2026, FDA lists 36 applications for Lansoprazole (sold as Prevacid, Prevacid Iv, Prevacid 24 Hr and others), first approved May 10, 1995, with 14 new uses approved and 0 published complete response letters.
| Lansoprazole | Part D | $46.5M | -2% | 344,808 |
| Prevacid | Part D | $7.9M | -15% | 1,706 |
| May 10, 1995 | PrevacidNDA 20406 · New molecular entity | Takeda Pharms USA | 72 | Marketed |
| May 3, 2001 | PrevacidNDA 21281 · New dosage form | Takeda Pharms Na | 14 | Discontinued |
| Aug 30, 2002 | PrevacidNDA 21428 · New dosage form | Takeda Pharms USA | 26 | Marketed |
| May 27, 2004 | Prevacid IvNDA 21566 · New dosage form | Takeda Pharms Na | 4 | Discontinued |
| May 18, 2009 | Prevacid 24 HrNDA 22327 · New formulation or manufacturer | Perrigo Pharma Intl | 18 | Marketed |
| Nov 10, 2009 | LansoprazoleANDA 90763 | Mylan Pharms Inc | 9 | Marketed |
| Nov 10, 2009 | LansoprazoleANDA 77255 | Teva Pharms | 13 | Marketed |
| Apr 23, 2010 | LansoprazoleANDA 90331 | Sandoz | 13 | Discontinued |
| Oct 15, 2010 | LansoprazoleANDA 78730 | Ani Pharms | 0 | Discontinued |
| Oct 15, 2010 | LansoprazoleANDA 91269 | Dr Reddys Labs Ltd | 14 | Marketed |
| May 18, 2012 | LansoprazoleANDA 202727 | Glenmark Pharms | 2 | Marketed |
| May 18, 2012 | LansoprazoleANDA 202194 | Dr Reddys Labs Ltd | 7 | Marketed |
| May 18, 2012 | LansoprazoleANDA 202319 | Perrigo R And D | 8 | Marketed |
| Sep 14, 2012 | LansoprazoleANDA 202176 | Apotex | 4 | Marketed |
| Dec 18, 2012 | LansoprazoleANDA 201921 | Natco Pharma Ltd | 5 | Marketed |
| Aug 19, 2013 | LansoprazoleANDA 202366 | Zydus Hlthcare | 6 | Marketed |
| Sep 13, 2013 | LansoprazoleANDA 91509 | Sun Pharm | 7 | Discontinued |
| Sep 13, 2013 | LansoprazoleANDA 202637 | Sun Pharm | 6 | Discontinued |
| Sep 16, 2013 | LansoprazoleANDA 91212 | Krka Tovarna Zdravil | 1 | Discontinued |
| Jan 13, 2016 | LansoprazoleANDA 203306 | Natco | 3 | Marketed |
| Jun 1, 2016 | LansoprazoleANDA 203187 | Mylan | 1 | Discontinued |
| Jun 7, 2016 | LansoprazoleNDA 208025 · New formulation or manufacturer | Dexcel | 9 | Marketed |
| Jul 25, 2016 | LansoprazoleANDA 203203 | Xiromed | 7 | Marketed |
| Oct 14, 2016 | LansoprazoleANDA 203957 | Ajanta Pharma Ltd | 8 | Discontinued |
| Aug 30, 2017 | LansoprazoleANDA 205868 | Adaptis | 2 | Marketed |
| Sep 21, 2017 | LansoprazoleANDA 208784 | Teva Pharms USA | 6 | Marketed |
| Sep 28, 2017 | LansoprazoleANDA 207156 | Chartwell Molecular | 7 | Marketed |
| Sep 29, 2017 | LansoprazoleANDA 207157 | Lannett Co Inc | 2 | Discontinued |
| Oct 17, 2018 | LansoprazoleANDA 203964 | Novitium Pharma | 0 | Discontinued |
| Nov 27, 2018 | LansoprazoleANDA 200816 | Zydus Pharms | 3 | Marketed |
| Nov 28, 2018 | LansoprazoleANDA 202396 | Mylan | 4 | Marketed |
| Jan 18, 2019 | LansoprazoleANDA 207394 | Alkem Labs Ltd | 4 | Marketed |
| May 18, 2020 | LansoprazoleANDA 203083 | Hetero Labs Ltd Iii | 2 | Marketed |
| Feb 1, 2021 | LansoprazoleANDA 210465 | Dr Reddys | 2 | Marketed |
| Mar 28, 2023 | LansoprazoleANDA 207167 | Aurobindo Pharma Ltd | 1 | Marketed |
| Nov 4, 2024 | LansoprazoleANDA 208671 | Macleods Pharms | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA